BioNTech (NASDAQ:BNTX) Earns “Buy” Rating from Canaccord Genuity Group

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reiterated by Canaccord Genuity Group in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $171.00 target price on the stock. Canaccord Genuity Group’s target price suggests a potential upside of 71.48% from the company’s current price.

Other research analysts have also recently issued research reports about the stock. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $90.00 to $137.00 in a research note on Friday, November 8th. Bank of America lifted their price target on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. HSBC lifted their price target on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. UBS Group lifted their price target on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 18th. Finally, TD Cowen dropped their price target on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research note on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $137.54.

BioNTech Trading Down 3.7 %

Shares of BNTX stock opened at $99.72 on Thursday. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average is $113.54 and its 200 day moving average is $97.18. The stock has a market capitalization of $23.91 billion, a P/E ratio of -47.49 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter last year, the company posted $0.73 earnings per share. The firm’s quarterly revenue was up 38.9% on a year-over-year basis. Research analysts expect that BioNTech will post -3.47 earnings per share for the current year.

Institutional Trading of BioNTech

A number of institutional investors and hedge funds have recently bought and sold shares of BNTX. Janney Montgomery Scott LLC bought a new stake in BioNTech in the 1st quarter valued at $314,000. ProShare Advisors LLC increased its holdings in BioNTech by 10.4% in the 1st quarter. ProShare Advisors LLC now owns 6,785 shares of the company’s stock valued at $626,000 after acquiring an additional 637 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in BioNTech by 2.3% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company’s stock valued at $904,000 after acquiring an additional 223 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of BioNTech by 51.3% in the 1st quarter. Acadian Asset Management LLC now owns 111,398 shares of the company’s stock worth $10,275,000 after buying an additional 37,792 shares during the last quarter. Finally, Covestor Ltd increased its holdings in shares of BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after buying an additional 133 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.